法国社区药房调查:育龄女性丙戊酸处方与调剂条件依从性
该研究通过2018年和2020年两次前瞻性观察调查,评估法国社区药房对育龄女性口服丙戊酸处方与调剂条件的依从性,条件包括专科医生年度处方和签署风险确认表。结果显示依从率从2018年的42%(95%CI 39-45)升至2020年的47%(95%CI 43-50),神经科医生处方的依从率(≥60%)高于其他处方者(≤45%)。
要点
- 育龄女性丙戊酸处方需专科医生年度处方和签署风险确认表。
- 2018年依从率42%,2020年47%,整体仍不足半数。
- 神经科医生处方的依从率高于其他处方者。
核心结论
- 法国育龄女性口服丙戊酸处方与调剂条件依从性在2018年为42%(95%CI 39-45),2020年为47%(95%CI 43-50),整体仍不理想。
- 神经科医生处方的依从率(≥60%)高于其他处方者(≤45%)。
研究设计与样本
- 2018年至2020年间在法国代表性社区药房样本中开展两次前瞻性观察调查。
- 数据来自2-49岁女性患者携带丙戊酸处方到参与药房调剂的情况。
- 2018年分析1067张丙戊酸处方,2020年分析824张处方,其中≥92%为育龄女性。
主要发现
- 2018年处方与调剂条件符合率为42%(95%CI 39-45),2020年为47%(95%CI 43-50)。
- 神经科医生处方的依从率≥60%,其他处方者≤45%。
- 多数处方(≥92%)针对育龄女性。
关键数值与推荐
- 口服丙戊酸处方与调剂条件包括:专科医生年度处方和签署风险确认表。
- 2018年依从率42%(95%CI 39-45),2020年47%(95%CI 43-50)。
- 神经科医生处方依从率≥60%,其他处方者≤45%。
临床怎么用
- 社区药师应核对育龄女性口服丙戊酸处方是否由专科医生开具并附签署的风险确认表。
- 对非神经科医生处方的丙戊酸,药师应加强风险确认表签署的核查与提醒。
- 提高医务人员对风险最小化措施的认知与依从性,以限制丙戊酸产前暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Prenatal exposure to valproate and related substances is associated with a risk of malformations and/or neurodevelopmental disorders. In France, prescription and dispensing conditions of oral valproate forms are subject to risk minimization measures for girls and women of childbearing potential with the aim to limit pregnancy under this treatment. These risk minimization measures were issued in 2015 and were strengthened in 2018. OBJECTIVE: We aimed to evaluate compliance with prescription and dispensing conditions of valproate for oral administration: an annual prescription from a specialist and a signed risk acknowledgment form. METHODS: Two prospective observational surveys were carried out between 2018 and 2020 on a representative sample of French community pharmacies. Data were collected from female patients aged 2-49 years presenting to one of the participating pharmacies with a valproate prescription. RESULTS: In total, 1067 and 824 valproate prescriptions were analyzed in 2018 and 2020, respectively, the majority of which were for girls and women of childbearing potential (≥ 92%). The prescription and dispensing conditions for valproate were met in 42% of cases (95% confidence interval 39-45) in 2018 and in 47% of cases (95% confidence interval 43-50) in 2020. Compliance levels were higher for prescriptions from neurologists (≥ 60%) than from other prescribers (≤ 45%). CONCLUSIONS: In France, the implementation of specific risk minimization measures for girls and women of childbearing potential with respect to oral valproate forms and related substances requires a stronger involvement of stakeholders. Increased awareness and compliance among healthcare professionals regarding risk minimization measures could limit prenatal exposure to valproate.
引用
- Fauvelle K, Bigna JJ. Compliance with Prescribing and Dispensing Conditions for Valproate and Related Substances in Girls and Women of Childbearing Potential: A Survey of Community Pharmacists in France. Drug Saf. 2022. PMID: 36287388. doi:10.1007/s40264-022-01234-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。